FDA clearance allows Prelude Therapeutics to advance PRT13722 into a Phase 1 study for HR+/HER2- breast cancer. The study is expected to begin enrolling patients in the fourth quarter of 2026 and will test the oral KAT6A degrader alone and with endocrine or targeted therapies, creating a defined clinical development milestone for investors.

Key Highlights

  • Patient enrollment for the PRT13722 study is anticipated in the fourth quarter of 2026.
  • The open-label, multicenter trial will assess safety, tolerability, pharmacokinetics, pharmacodynamics and antitumor activity.
  • Investor materials identify early 2027 data for Prelude’s JAK2V617F mutant selective JH2 inhibitor program.

The first-in-human trial will evaluate the candidate in adults with locally advanced or metastatic disease.

PRT13722 Phase 1 Study Scope

The open-label, multicenter study will assess safety, tolerability, pharmacokinetics, pharmacodynamics and antitumor activity. Prelude (NASDAQ: PRLD) describes the candidate as an oral, selective KAT6A degrader. The program is being developed for patients with HR-positive, HER2-negative breast cancer.

Fourth-Quarter 2026 Enrollment Plan

Those materials identify a Phase 1 start in the fourth quarter of 2026 for KAT6A selective degraders in HR+ breast cancer and other malignancies. The presentation identifies early data in 2027 for JAK2V617F mutant selective JH2 inhibitors in myeloproliferative neoplasms.